Phase I/IB Multi-Center Study of Irreversible EGFR/HER2 Tyrosine Kinase Inhibitor Afatinib (BIBW2992)in Combination with Capecitabine for Advanced Solid Tumors and Pancretico- Biliary Cancers
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to test the safety and antitumor activity of the combination of two drugs, Afatinib and capecitabine, and to see what effects (good and bad) these drugs have on you and your cancer.
Description
The purpose of this study is to test the safety and antitumor activity of the combination of two drugs, Afatinib and capecitabine, and to see whate effects these drugs have on Advanced Solid Tumors and Pancreatico-Biliary Cancers.
Details
| Condition | Advanced Solid Tumor, Pancretico- Biliary Cancer |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX5937 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.